Brawn Biotech (BOM:530207) Research & Development: ₹0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

BOM:530207 Brawn Biotech Ltd BOM:530207
55 GF Score
Price ₹20.21
GF Value ₹20.49
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Brawn Biotech Research & Development?

Brawn Biotech BOM:530207 +4.99% 55 Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus rates BOM:530207 with a GF Score™ of 55/100 and a GF Value™ of ₹20.49 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Brawn Biotech's Research & Development for the three months ended in Mar. 2026 was ₹0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was ₹0.0 Mil.

Brawn Biotech  (BOM:530207) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Brawn Biotech Research & Development Related Terms

Brawn Biotech Research & Development Historical Data

* Premium members only.

The historical data trend for Brawn Biotech's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Brawn Biotech Research & Development Chart

Brawn Biotech Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Brawn Biotech Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
BOM:530207
55GF Score
Brawn Biotech Ltd BOM:530207
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Brawn Biotech Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of ₹0.0 Mil mean?
Brawn Biotech (BOM:530207) has a Research & Development of ₹0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Brawn Biotech and its competitors.
Is Brawn Biotech's Research & Development too high?
Brawn Biotech's current Research & Development is ₹0.0 Mil. Overall, Brawn Biotech has a GF Score™ of 55/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Brawn Biotech's Research & Development compare to ZTS?
Brawn Biotech's Research & Development of ₹0.0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Drug Manufacturers company?
A good Research & Development depends on the Drug Manufacturers industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Brawn Biotech and its competitors. Brawn Biotech's current Research & Development is ₹0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Brawn Biotech stock overvalued right now?
Based on GuruFocus' analysis, Brawn Biotech (BOM:530207) is currently considered Fairly Valued. The stock's GF Value™ is ₹20.49, compared to a current price of ₹20.21 — trading 1.4% below its estimated fair value. The current Research & Development is ₹0.0 Mil. Brawn Biotech's overall GF Score™ is 55/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Brawn Biotech (BOM:530207), the current Research & Development is ₹0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Brawn Biotech (BOM:530207) Overvalued in 2026?

Based on GuruFocus' analysis, Brawn Biotech stock appears to be undervalued. The current stock price of ₹20.21 is trading 1.4% below its estimated GF Value™ of ₹20.49. GuruFocus considers Brawn Biotech to be Fairly Valued.

Key valuation signals for BOM:530207:

  • Research & Development: ₹0.0 Mil
  • GF Value™: ₹20.49 vs. price of ₹20.21 (1.4% below fair value)
  • GF Score™: 55/100 with 5 warning signs

No single metric tells the full story. See the BOM:530207 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Brawn Biotech Business Description

Address Lajpat Nagar-1, C-64, First Floor, New Delhi, IND, 110024
Brawn Biotech Ltd is a healthcare company. It is engaged in the business activity of wholesale of pharmaceutical and medical goods. The company's pharmaceutical goods cover product segments like Antibacterial, Cardiovascular, Anti-diabetic, Analgesics, Gastrointestinal, Antifungals, Skin Care, Antipsychotics, Anti-asthmatic, Antacids, Antimalarial, and Nutritionals.
55GF Score

Get the complete analysis for BOM:530207

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹20.21
Price
₹20.49
GF Value